Rockwell Medical (NASDAQ:RMTI) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Rockwell Medical (NASDAQ:RMTI) posted its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03), Zacks reports. The company had revenue of $17.34 million for the quarter, compared to the consensus estimate of $17.95 million. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%.

Here are the key takeaways from Rockwell Medical’s conference call:

• Rockwell raised 2026 guidance to $70–75M in net sales, projects 18–22% gross margin, expects $1–2M Adjusted EBITDA, positive operating cash flow, and targets positive net income in H2 2026.
• Operational changes — including activation of two automated liquid lines expected to boost output ~50% — should materially lower manufacturing cost per bottle and are estimated to add ~$3M of gross profit (roughly half realizable in 2026).
• Q1 results showed $17.3M in sales (down 8% YoY due to a large customer’s volume decline), gross profit of $2.9M and 17% gross margin (up from 16%); Adjusted EBITDA improved slightly to a negative $0.3M, and cash was $23.9M at quarter end.
• Customer diversification and commercial traction strengthened — ~300 customers covering 1,400+ facilities (including all five leading U.S. dialysis providers), sales in 30+ countries, and recent contract renewals/new wins with improved pricing and product mix.
• Management reiterated long-term targets (by 2029: >$100M sales, gross margin approaching 30%, and annual profitability of $5–10M), but these remain forward‑looking goals subject to execution and risks.

Rockwell Medical Stock Performance

NASDAQ RMTI traded up $0.05 during trading hours on Friday, reaching $0.83. The company’s stock had a trading volume of 290,195 shares, compared to its average volume of 567,665. The company has a current ratio of 3.98, a quick ratio of 3.63 and a debt-to-equity ratio of 0.25. The business has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $0.96. Rockwell Medical has a 52 week low of $0.74 and a 52 week high of $2.10. The stock has a market cap of $32.85 million, a PE ratio of -5.56 and a beta of 1.65.

Institutional Trading of Rockwell Medical

A number of institutional investors and hedge funds have recently made changes to their positions in RMTI. XTX Topco Ltd lifted its holdings in shares of Rockwell Medical by 286.5% in the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after purchasing an additional 46,029 shares during the last quarter. Jane Street Group LLC bought a new position in Rockwell Medical during the 4th quarter worth $84,000. Geode Capital Management LLC grew its stake in Rockwell Medical by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after buying an additional 41,668 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after buying an additional 148,737 shares during the period. 23.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on RMTI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Tuesday, April 21st. Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, HC Wainwright dropped their price target on Rockwell Medical from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $2.00.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.